166 related articles for article (PubMed ID: 38367070)
21. Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma.
Liu Z; Liu L; Guo C; Yu S; Meng L; Zhou X; Han X
Int Immunopharmacol; 2021 Dec; 101(Pt B):108340. PubMed ID: 34789428
[TBL] [Abstract][Full Text] [Related]
22. Harnessing neutrophil plasticity for HCC immunotherapy.
Ramon-Gil E; Geh D; Leslie J
Essays Biochem; 2023 Sep; 67(6):941-955. PubMed ID: 37534829
[TBL] [Abstract][Full Text] [Related]
23. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma.
Hong YK; Li Y; Pandit H; Li S; Pulliam Z; Zheng Q; Yu Y; Martin RCG
Cell Immunol; 2019 Feb; 336():66-74. PubMed ID: 30626493
[TBL] [Abstract][Full Text] [Related]
25. Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma.
Yu Z; Li Y; Li Y; Zhang J; Li M; Ji L; Tang Y; Zheng Y; Sheng J; Han Q; Li F; Guo J; Wang L; Sun X; Gao Y; Feng H
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618286
[TBL] [Abstract][Full Text] [Related]
26. Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma.
Weng J; Liu S; Zhou Q; Xu W; Xu M; Gao D; Shen Y; Yi Y; Shi Y; Dong Q; Zhou C; Ren N
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37385725
[TBL] [Abstract][Full Text] [Related]
27. Spatial maps of hepatocellular carcinoma transcriptomes reveal spatial expression patterns in tumor immune microenvironment.
Wang YF; Yuan SX; Jiang H; Li ZX; Yin HZ; Tan J; Dai ZH; Ge CM; Sun SH; Yang F
Theranostics; 2022; 12(9):4163-4180. PubMed ID: 35673582
[No Abstract] [Full Text] [Related]
28. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
29. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
30. An immune-related biomarker index for predicting the effectiveness of immunotherapy and prognosis in hepatocellular carcinoma.
Wu X; Jin B; Liu X; Mao Y; Wan X; Du S
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10319-10333. PubMed ID: 37273105
[TBL] [Abstract][Full Text] [Related]
31. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
[TBL] [Abstract][Full Text] [Related]
32. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.
Peng Y; Liu C; Li M; Li W; Zhang M; Jiang X; Chang Y; Liu L; Wang F; Zhao Q
Cancer Cell Int; 2021 Feb; 21(1):98. PubMed ID: 33568167
[TBL] [Abstract][Full Text] [Related]
33. Emerging Role of Circular RNAs in Hepatocellular Carcinoma Immunotherapy.
Abaza T; El-Aziz MKA; Daniel KA; Karousi P; Papatsirou M; Fahmy SA; Hamdy NM; Kontos CK; Youness RA
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003674
[TBL] [Abstract][Full Text] [Related]
34. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma.
He Q; Yang J; Jin Y
Front Immunol; 2022; 13():869993. PubMed ID: 35493518
[TBL] [Abstract][Full Text] [Related]
35. Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients.
Huang S; Zhang J; Lai X; Zhuang L; Wu J
Front Mol Biosci; 2021; 8():781307. PubMed ID: 35004851
[No Abstract] [Full Text] [Related]
36. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
37. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.
Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H
J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546
[TBL] [Abstract][Full Text] [Related]
38. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
39. Analysis of angiogenesis-related subtypes of hepatocellular carcinoma and tumor microenvironment infiltration feature in hepatocellular carcinoma.
Li W; Wu R; Zhang S; Zhao Y; Li L; Hu Z; Su Q; Mang Y; Zhang X; Dong Y; Zheng K; Ran J; Li L
Clin Transl Oncol; 2023 Jul; 25(7):2099-2115. PubMed ID: 36708372
[TBL] [Abstract][Full Text] [Related]
40. Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.
Xu L; Zheng Q; Liu W
BMC Cancer; 2022 Mar; 22(1):229. PubMed ID: 35236323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
